S14161 delayed the tumor growth in leukemia xenografts. K562 (A,B) and U937 (C,D) leukemia cells were injected subcutaneously into SCID mice. When the tumors were palpable, mice were treated with S14161 (100 mg/kg) or vehicle control intraperitoneally for 10 days (n = 10 per group). Tumor growth (A,C) and body weight (B,D) were monitored every other day. Data represent the mean ± SD of a representative experiment. *P < .05, **P < .001 by Student t test. (E) Tumor samples from U937 xenograft mice models after 10 days of treatment with S14161 were excised. Total AKT and cyclin D3 (CCND3) were evaluated by immunoblotting with specific antibodies (left). Relative expression of AKT (middle) and CCND3 (right) was quantitated by densitometric analysis based on the immunoblotting assay result (left). *Significant difference (P < .01) between vehicle control and S14161 treatment.